Literature DB >> 30990261

Clinical Credence - SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease.

Julie R Ingelfinger1, Clifford J Rosen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30990261     DOI： 10.1056/NEJMe1904740

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Management of Hyperglycemia in Older Adults with Type 2 Diabetes.

Authors:  Gunjan Y Gandhi; Arshag D Mooradian
Journal:  Drugs Aging       Date:  2021-12-18       Impact factor: 3.923

Review 2.  Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.

Authors:  Alejandrina M Castañeda; Amanda Dutra-Rufato; Maria J Juarez; Luis Grosembacher; Henry Gonzalez-Torres; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2020-08-07       Impact factor: 2.370

Review 3.  RIPK3: A New Player in Renal Fibrosis.

Authors:  Ying Shi; Xinming Chen; Chunling Huang; Carol Pollock
Journal:  Front Cell Dev Biol       Date:  2020-06-16

4.  Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus.

Authors:  Sheeba Ba Aqeel; Minghao Ye; Jan Wysocki; Alejandro Sanchez; Ahmed Khattab; Enrique Lores; Alfred Rademaker; Xiaoyu Gao; Ionut Bebu; Robert G Nelson; Mark Molitch; Daniel Batlle
Journal:  Physiol Rep       Date:  2019-10

5.  S-Nitrosylation of RhoGAP Myosin9A Is Altered in Advanced Diabetic Kidney Disease.

Authors:  Qi Li; Delma Veron; Alda Tufro
Journal:  Front Med (Lausanne)       Date:  2021-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.